Abstract. Novel treatment options are urgently required for patients with glioma who are not effectively treated through standard therapy. Human sodium iodide symporter (hNIS) is a molecular target of certain tumors types. 
I were compared in hNIS-mediated gene imaging and therapy in the present study. Recombinant human brain glioma cell line U87 was transfected with a recombinant lentiviral vector containing hNIS (U87-hNIS). U87-0 cell line transfected with blank lentivirus was prepared as a control. In vitro, the 188 Re and 131 I uptake of U87-hNIS cells were 21.3-times and 25.9-times that of the control groups, however the excretion rate of the two nuclides was very rapid, and the half-life was only ~4 min. Sodium perchlorate inhibited hNIS-mediated 188 Re and 131 I uptake to levels observed in the control groups. 188 Re and 131 I were able to kill U87-hNIS cells selectively, with a survival of only 21.6 and 36.2%, respectively. U87-hNIS nude mice appeared to accumulate 188 Re, with a ratio of radioactivity counts between tumor and non-tumor sites of ~13.5 compared with 10.3 of 131 I 1 h after radionuclide injection. In contrast with in vitro studies, U87-hNIS cells demonstrated a notable increase in 188 Re retention in vivo, even 24 h after 188 Re injection. U87-hNIS cells also exhibited increased 131 I retention in vivo; however, as the time increased, 131 I was rapidly released with the tumor no longer able to be imaged 24 h after 131 I injection. Following treatment, U87-hNIS tumors experienced a volume reduction of 24.1%, whereas U87-0 cells demonstrated an increase of 28.8%. 188 Re and
Introduction
Glioma is one of the most common malignant tumor types globally with high morbidity and mortality. To date, surgical resection and radiotherapy remain the primary methods used for the treatment of glioma (1, 2) . Radiotherapy requires at least 55 Gy of external radiation to control the tumor, however, a radiation dose of >60 Gy often results in normal brain tissue necrosis (3) (4) (5) . Therefore, novel therapeutic strategies are required. Sodium iodide symporter (NIS) is a type of cell membrane glycoprotein that mediates the active uptake of iodine in the thyroid and other types of tissues (6) . Gene therapy is an important alternative for the treatment of tumors; for example, radioiodine treatment of extra-thyroidal cancer via the ectopic transfer of the NIS gene into otherwise non-NIS-expressing cancer. A number of studies have successfully obtained ectopic expression of NIS in different tumors through gene transfer (7) (8) (9) (10) . The dual function of NIS as a diagnostic and therapeutic gene thereby allows easy monitoring of functional NIS expression using γ camera imaging techniques prior to the application of a therapeutic radionuclide dose (11) . Our previous studies (12) (13) (14) (15) demonstrated that baculovirus-mediated human NIS (hNIS) expression may mediate multiple tumor uptake of 131 I, providing a promising target for gene therapy. In previous studies, extra-thyroidal tissues have generally not been able to mediate iodide organification following NIS gene transfer, therefore rapid outflow of 131 I resulted in a decreased radiation dose able to affect the activity of tumor cells, thus decreasing the curative effect (16) . The use of alternative NIS-transported radioisotopes with a higher energy than 131 I may improve the efficacy of NIS-mediated radionuclide targeted therapy (17, 18) . 188 Re is a type of short physical half-life radionuclide (0.71 days), which has been applied to treat various diseases, including prostate carcinoma, hepatoma carcinoma, breast carcinoma, bladder carcinoma, refractory arthritis and coronary beta-brachytherapy (19) (20) (21) (22) 
Materials and methods
Plasmid construction, lentivirus preparation and U87 cell transfection with lentivirus. Human NIS gene was obtained in the form of a pcDNA3.1-hNIS plasmid (provided by Dr Sissy Jhiang from Ohio University, OH, USA). U87 glioma cell line [American Type Culture Collection (ATCC), Manassas, VA, USA] was maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.; 5% CO 2 , 37˚C). The plasmid containing hNIS was packaged into lentivirus vector (Thermo Fisher Scientific, Inc.) and named as Lenti-CMV-hNIS. To generate cell line expressing hNIS controlled by cytomegalovirus-enhancer/promoter, Lenti-CMV-hNIS was added to U87 cells at a multiplicity of infection of 2.0, then were selected for further study after 3 weeks. The transfected cell line stably expressing hNIS was named U87-hNIS. U87-hNIS was validated by radionuclide uptake experiments. Cells were inoculated with DMEM containing 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin in 24-well plates 24 h prior to the experiment to achieve a density of 10 5 cells per well at the day of experiment.
In vitro radioisotope uptake experiments.
188 Re was eluted from a 188 W/ 188 Re generator (Jiangsu ReTai Pharmaceutical Biotechnology Co., Ltd., Changzhou, China) using 0.9% saline.
131 I was supplied by Shanghai Kexin Biotech Co., Ltd. (Shanghai, China). In vitro 188 Re/ 131 I uptake experiments of U87-hNIS cells expressing hNIS were performed as Weiss and Grollman (25) described previously, with minor modifications. All data were corrected for attenuation. U87-hNIS cells were washed with 0.5 ml buffered Hanks' balanced salt solution (bHBSS; containing 10 µM HBSS and buffered with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.3), incubated in 0.5 ml bHBSS (containing 3.7 kBq 188 Re/ 131 I) liquid for 1, 2, 5, 10, 20, 30, 60 and 120 min respectively, then washed two times with ice-cold bHBSS, incubated with 1 ml of 100% dehydrated ethanol for 20 min, followed by cell lysis (using trypsin and 0.25% EDTA; Gibco; Thermo Fisher Scientific, Inc.). Finally, the radioactivity (count per min) was detected using a well gamma-counter (Shanghai Institute of Nuclear Research Rihuan Instrument Co., Shanghai, China) and compared with background, in order to achieve a ratio. All the following experiments were conducted in triplicate.
Sodium perchlorate inhibition study. The specificity of 188 Re/ 131 I uptake was investigated in the present study. U87-hNIS cells (at a density of 10 5 ) were incubated with sodium perchlorate (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and 3.7 kBq 188 Re/ 131 I in DMEM containing 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin (5% CO 2 , 37˚C) for 30 min, in which the concentration of sodium perchlorate was 0, 1, 2, 5, 10, 20, 50 and 100 µM, respectively. Thereafter, the cells were washed with bHBSS twice, lysed (using trypsin and 0.25% EDTA; Gibco; Thermo Fisher Scientific, Inc.) at room temperature for three min, and their radioactivity measured, according to the methods aforementioned.
Radioisotope efflux study in vitro.
The 188 Re/ 131 I efflux kinetics of U87-hNIS cells were investigated as previously described (25) . U87-hNIS cells (at a density of 10 5 ) were incubated with 188 Re/ 131 I (3.7 kBq/well) at 37˚C for ~30 min. The culture medium (DMEM containing 10% fetal bovine serum) was then replaced with nonradioactive bHBSS. Cells were incubated for 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20 min and immediately lysed using trypsin and 0.25% EDTA (Gibco; Thermo Fisher Scientific, Inc.). Subsequently, cells were extracted with 1 ml dehydrated alcohol and the radioactivity in the cells was measured as aforementioned.
In vitro assessment of radioisotope toxicity by clonogenic assay. Prior to the experiment, U87-hNIS cells were cultured in 24-well plates, in order to achieve a density of 10 5 cells/well at the day of study. As presented in Table I , cells were divided into five groups. Group 1 comprised U87-hNIS cells washed with bHBSS with 740 kBq 188 Re, then cultured (5% CO 2 , 37˚C) for 7 h. Group 2 was processed much the same as group 1, with the exception that 188 Re was replaced with 131 I. Groups 3 and 4 were non-transfected U87 cells with 188 Re and 131 I, respectively. Group 5 comprised non-transfected U87 cells without the addition of any radionuclide. Groups 3, 4 and 5 all served as controls. The 5 groups of cells were then washed and lysed as described above, and seeded in 6-well plates at a density of 200 cells/well. The cells were cultured for 7 days (5% CO 2 at 37˚C). Following removal of the culture medium as aforementioned, cells were stained with crystal violet solution (0.1%) at room temperature for 10 min and the colonies >30 cells were counted using an optical microscope (x100 magnification; CKX41; Olympus Corporation, Tokyo, Japan). Results were expressed as the percentage of surviving cells compared with untreated U87 cells (Group 5).
Animal models. A total of 18 female 5-week-old athymic Balb/c nude mice (18-20 g in weight) were used (Shanghai Laboratory Animal Centre Chinese Academy of Sciences, Shanghai, China). A full light-dark cycle with 10 h of light and 14 h of darkness each day was applied, with conditions including a temperature of 26-28˚C, a humidity of 40-60%, and general feed and drinking water provided. Mice were sacrificed 4 weeks after the first intravenous injections of 188 Re or 131 I. Animal experiments were approved by the Ethics Committee and Animal Care Committee of Shanghai JiaoTong University, School of Medicine (Shanghai, China). A xenograft model was generated by subcutaneous injection of U87-hNIS cells (5x10 6 cells, suspended in 150 µl PBS) into the right armpit of the mice. Subsequently, ~6 weeks following inoculation, the tumor diameters reached 0.8-1.0 cm, which could be used for imaging and therapies. I injection. Each image lasted for 3 min. The matrix size was 256x256. Region of interest was placed on the area of tumor and the contralateral axillary, and the ratio of radioactivity counts between tumor and non-tumor sites (T/NT) at each time point was measured.
Tumor therapy studies were performed in U87-hNIS nude mice at the same time. In the present study, no animal presented with multiple tumors, and when the tumor diameter of nude mice grew to 0.8-1.0 cm in diameter (the minimum and maximum diameter exhibited by a single tumor in the present study were 0.82 and 0.96 cm, respectively), they were randomly divided into three groups (n=6). Group I uptake in U87-hNIS cells is mediated by functional hNIS expression.
Radionuclide efflux assay.
188 Re/ 131 I efflux assays were performed 30 min after the addition of 188 Re/ 131 I into the cultured cells (the aforementioned cell uptake experiment identified that the highest intracellular uptake was obtained at 30 min). The culture medium containing 188 Re/ 131 I was replaced by nonradioactive DMEM, the remaining 188 Re/ 131 I activity in U87-hNIS cell lysate was determined. As presented in Fig. 3 , the intracellular radionuclides were released rapidly I reached a peak 1 h after administration (T/NT, 13.5±3.2 and 10.3±2.1, respectively).
188 Re remained at a steady level until 24 h (T/NT, 11.6±2.1), whereas 131 I experienced limited retention at 24 h (T/NT, 3.9±0.7). Thyroid naturally expressing NIS markedly accumulated 131 I 24 h after injection, whereas 188 Re demonstrated limited accumulation (Fig. 5) . As a result of lacking organification, 188 Re cannot be retained in the thyroid for a prolonged period of time, therefore its half-life is relatively short in the thyroid and may protect the thyroid from hypothyroidism. In contrast, 131 I can be organified by the thyroid, which alongside a long half-life may increase the risk of hypothyroidism.
A ) (P<0.01; Fig. 7) . Following therapy, 188 Re treated U87-hNIS tumors experienced a volume 
Discussion
NIS-mediated radionuclide therapy possesses several advantages (27) , making it an attractive approach for glioma imaging and therapies. It does not require complex radiolabeling procedures, it also is small-sized allowing it to penetrate the blood brain barrier and diffuse into the tumor (28) . Radioisotopes exhibit the potential of a bystander effect, which may destroy tumor cells without hNIS expression by radionuclides emitted from surrounding hNIS expression tumor cells (29) . The hNIS gene is not expressed in normal cells however is in glioma cells (30) , this indicates that it may assist in improving the specificity of tumor therapy and decreasing the damage to normal brain tissue.
131
I is an isotope commonly used in NIS-associated radionuclide therapy studies (31) . However, as the radiation energy is not high enough, therapeutic efficacy of 131 I is limited (3). The use of a high-energy radionuclide also transported by NIS including 188 Re, may be an effective strategy to improve therapeutic effect. A previous study demonstrated that 188 Re and 125 I share similar biodistribution patterns in mice, with the exception of the thyroid gland, as the thyroid gland has an organic function of iodine, which can retain 125 I (26 (33) . These attractive physical properties make 188 Re a promising candidate for tumor imaging and therapy (19) . 188 Re possesses a higher β energy, but relatively shorter physical half-life compared with 131 I (34) . Therefore, in the current study, the effects of 188 Re and 131 I in the treatment of glioma were compared in vivo and in vitro.
In the present study, it was demonstrated that a lentivirus containing CMV-hNIS expression cassette is able to transfect U87 cells, as revealed by efficient 188 Re/ 131 I uptake in U87-hNIS cells. 188 Re/ 131 I exhibit rapid uptake in U87-hNIS cells, and the dynamic uptake pattern of 188 Re/ 131 I was similar to that of previous studies (30, 31) . 188 Re uptake of U87-hNIS was up to 21.3-times that of the U87-0 control group, whereas 131 I uptake was up to 25.9-fold of that of the control group. The two isotopes experienced a plateau phase akin to previous studies (35, 36) , when the uptake and efflux of the isotopes reached a state of equilibrium (25) . As with previous NIS studies, radionuclide retention time was short, and rapid outflow remained a problem in the in vitro studies, in the present study. Neither 188 Re nor 131 I experienced a long retention time in vitro.
In the in vitro experiments, isotope flow was rapid, with the outflow kinetics of the two radionuclides being similar. In addition, the colony formation assay demonstrated that U87-hNIS cells could be killed effectively by 188 Re and 131 I. The absorbed dose of 188 Re was sufficiently high to selectively kill 78.4% of the cells, whereas 131 I was able to kill up to 63.8% of the cells. These data are sufficient to suggest that even with a lower uptake than that of 131 I, 188 Re may also be able to deliver a greater radiation dose to tumor cells, which is similar to the results reported by Kang et al (37) In the in vitro study, cells in the culture dishes were arranged in a single layer, which is not a three-dimensional structure. Conclusions from the cells cannot be applied to solid glioma with a three-dimensional structure, which requires further confirmation in xenografts. In vivo, U87-hNIS glioma cells are close to each other, which allows for rapid reuptake of radionuclides in the cells and serves as a mechanism for isotope trapping by glioma. The results of the in vivo imaging investigations in the present study suggested that 188 Re remained in U87-hNIS glioma cells even 24 h after administration, whereas a limited amount of 131 I was retained in the cells 24 h after treatment. The results of the present study suggest that 188 Re cannot be retained in the thyroid gland, as it cannot be organified. A previous study has reported a similar biodistribution pattern for 131 I and 188 Re (38) . In fact, the thyroid will decrease the competitive uptake of 188 Re, thereby decreasing thyroid injury and increasing tumor reuptake of 188 Re, which is an advantage of hNIS-mediated radionuclide therapy in non-thyroid tumors. In addition, the results of the present study demonstrated that the degree of 188 Re/ 131 I uptake and retention are sufficient to achieve tumor therapeutic effects. Following treatment for 4 weeks, there was a significant difference in tumor size between 188 Re treated U87-hNIS mice and 131 I treated U87-hNIS mice. The present study also possessed a number of limitations. A stable hNIS transfected cell line was used to express hNIS, which could not be used directly in clinical practice. As a result of the variation of hNIS transfection efficiency and the difference in specificity, actual clinical efficacy of 188 Re and 131 I requires further evaluation. It is reported that U87 MG ATCC cell line has been contaminated/misidentified, however it is most probably also a glioblastoma cell line (39) . hNIS mediates uptake of iodine in thyroid and numerous types of non-thyroid cells (6) , as a result, a number of previous studies have also successfully obtained ectopic expression of hNIS in different tumors by gene transfer (7-10). The main purpose of the present study was to compare the therapeutic effects of 188 Re and 131 I mediated by hNIS, rather than a study into the underlying molecular mechanisms of their effects, therefore the U87 cell line could be replaced with a variety of cell lines that express hNIS, as such the aforementioned misidentification/contamination issue is unlikely to have affected the outcomes of the present study.
In conclusion, the results of the present study demonstrated that 188 Re appeared to be more efficient than 131 I in the treatment of gliomas. The strategy appears to be a novel method for tumor imaging and therapy. However, improvements to decrease efflux and achieve increased radiation doses in the target tissue are still required.
